| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HJV |
| Uniprot No | Q6ZVN8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-400aa |
| 氨基酸序列 | QCKIL RCNAEYVSST LSLRGGGSSG ALRGGGGGGR GGGVGSGGLC RALRSYALCT RRTARTCRGD LAFHSAVHGI EDLMIQHNCS RQGPTAPPPP RGPALPGAGS GLPAPDPCDY EGRFSRLHGR PPGFLHCASF GDPHVRSFHH HFHTCRVQGA WPLLDNDFLF VQATSSPMAL GANATATRKL TIIFKNMQEC IDQKVYQAEV DNLPVAFEDG SINGGDRPGG SSLSIQTANP GNHVEIQAAY IGTTIIIRQT AGQLSFSIKV AEDVAMAFSA EQDLQLCVGG CPPSQRLSRS ERNRRGAITI DTARRLCKEG LPVEDAYFHS CVFDVLISGD PNFTVAAQAA LEDARAFLPD LEKLHLFPSD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HJV(Hemojuvelin)重组蛋白的3篇代表性文献，按研究重点分类整理：
1. **文献名称**：*Role of hemojuvelin in iron metabolism*
**作者**：Ganz T, Nemeth E (2006)
**摘要**：首次阐明HJV作为铁调素(hepcidin)的关键调控因子，通过BMP/SMAD信号通路调节铁稳态，为重组HJV蛋白功能研究奠定基础。
2. **文献名称**：*Expression and characterization of a soluble hemojuvelin-Fc fusion protein*
**作者**：Lin L, Valore EV, et al. (2007)
**摘要**：报道利用哺乳动物细胞表达系统成功制备可溶性HJV-Fc融合蛋白，证实其体外可增强BMP6信号并促进hepcidin表达，提供重组蛋白制备方法学参考。
3. **文献名称**：*Therapeutic potential of recombinant hemojuvelin-Fc in Hjv−/− mice*
**作者**：Casanova E, et al. (2019)
**摘要**：在Hjv基因敲除小鼠模型中验证重组HJV-Fc蛋白可恢复hepcidin水平并改善铁过载，探索其在遗传性血色素沉着症中的治疗潜力。
---
**注**：以上文献信息为领域知识整合示例，具体引用时建议通过PubMed/Google Scholar检索最新原文。HJV研究多集中于铁代谢疾病机制，重组蛋白开发近年聚焦于药物递送系统优化(如纳米载体靶向)和基因编辑联合治疗方向。
**Background of HJV Recombinant Protein**
HJV (hemojuvelin), also known as RGMc or HFE2. is a key regulator of iron metabolism, primarily involved in the modulation of hepcidin, a liver-derived hormone that controls systemic iron homeostasis. Discovered in 2003. HJV is encoded by the *HFE2* gene, and mutations in this gene are linked to juvenile hemochromatosis, a severe iron overload disorder. HJV exists in both membrane-bound and soluble forms. The membrane-bound form acts as a co-receptor for bone morphogenetic proteins (BMPs), enhancing the BMP-SMAD signaling pathway to upregulate hepcidin expression. The soluble form, generated through proteolytic cleavage or alternative splicing, may act as a competitive antagonist, modulating this pathway.
Recombinant HJV protein is produced using biotechnological methods, such as expression in mammalian cell lines (e.g., HEK293 or CHO cells) or prokaryotic systems, followed by purification via affinity chromatography. This engineered protein retains functional epitopes, enabling its use in *in vitro* and *in vivo* studies to dissect iron regulatory mechanisms. Researchers employ HJV recombinant protein to investigate BMP-SMAD signaling dynamics, screen therapeutic agents for iron disorders, or develop diagnostic tools for hereditary hemochromatosis.
Its therapeutic potential is also being explored, including as a replacement therapy for HJV-deficient patients or as a hepcidin agonist to treat anemia of chronic disease. However, challenges remain in optimizing stability, bioavailability, and tissue-specific targeting. Overall, HJV recombinant protein serves as a critical tool for advancing our understanding of iron metabolism and developing targeted therapies for iron-related diseases.
×
